Liminatus Pharma, Inc.

LIMN Nasdaq CIK: 0001971387

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Mailing Address 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Phone 213-273-5453
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
S-1 IPO registration statement February 11, 2026 View on SEC
8-K Current report of material events February 9, 2026 View on SEC
8-K Current report of material events January 26, 2026 View on SEC
8-K Current report of material events November 25, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
10-Q Quarterly financial report October 6, 2025 View on SEC
8-K Current report of material events August 25, 2025 View on SEC
3 Initial insider ownership report August 15, 2025 View on SEC
8-K Current report of material events August 14, 2025 View on SEC
S-1/A IPO registration amendment July 28, 2025 View on SEC

Material Events

8-K Legal Issue February 9, 2026
High Impact
  • Liminatus Pharma resolved a major legal dispute with Clear Street LLC.
  • The company avoided a substantial cash payment of over $8 million by issuing stock.
View Analysis
8-K Financial Distress January 26, 2026
High Impact
  • Liminatus has 180 calendar days to regain Nasdaq compliance.
  • Potential strategies for compliance include reverse stock split, positive clinical trial results, strategic partnerships, or a successful capital raise.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.